Evotec AG has entered a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat diabetes and obesity, as well as co-morbidities such as nonalcoholic steatohepatitis (NASH), cardiovascular diseases, and diabetic kidney disease. Financial terms were not disclosed. Evotec will apply its drug discovery platform, especially in ligand-based design, to design novel, safe and efficacious products to address diabetes and associated morbidities. Once suitabl...